Cross-buyer launch support and health-economic evidence services
Medical-device, diagnostic, digital-health, pharmaceutical and biotechnology vendors buying integrated launch support, health-economic evidence development and cross-functional mar
Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Market access, reimbursement and health-economic services
Health-economic assessments, reimbursement dossiers, pricing analysis, payer-engagement strategy and commercial launch support for technologies.
Split by customer type.
Medical-device, diagnostic, digital-health, pharmaceutical and biotechnology vendors buying integrated launch support, health-economic evidence development and cross-functional mar
Medical-device and diagnostic vendors buying evidence packages, reimbursement dossiers and payer-facing health-economic analyses to secure public reimbursement and coverage for dev
Pharmaceutical and biotechnology companies buying reimbursement dossiers, HTA submissions and health-economic analyses to obtain pricing and access for medicines and biologics.
Medical-device and diagnostic vendors buying pricing analysis, market-access strategy and payer-engagement planning to set launch prices and secure commercial access.
Pharmaceutical and biotechnology companies buying pricing analytics, launch sequencing, payer-engagement strategy and commercial-launch support to position medicines and biologics
$900M ($600M–$1.4B) · 2025 · Bottom-up
No source sizes this segment directly. Bottom-up: roughly 12,000-18,000 medtech, diagnostics and digital-health vendors in the US and EU with active products or in development [2] context; assume 25% engage external market-access support in a given year at USD 250k-500k average annual spend, giving USD 0.75-2.25B; midpoint USD 0.9B used. Growth assumed at 9% in line with the broader regulatory outsourcing CAGR range of 7.6-9.2% [5][9].
// Sell into Market access, reimbursement and health-economic services